The HER2 molecule is already used as a target for the targeted therapy ofbreast and gastric cancer with humanized anti-HER2 antibodies: trastuzumab(Herceptin, Herclon) and pertuzumab (Perjeta, Omnitarg) [70, 71]. Here, ERBB2 is linked to gastric cancer.